Cargando…

Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study

Purpose: In current radiotherapy (RT) planning and delivery, population-based dose-volume constraints are used to limit the risk of toxicity from incidental irradiation of organs at risks (OARs). However, weighing tradeoffs between target coverage and doses to OARs (or prioritizing different OARs) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rechner, Laura Ann, Modiri, Arezoo, Stick, Line Bjerregaard, Maraldo, Maja V., Aznar, Marianne C., Rice, Stephanie R., Sawant, Amit, Bentzen, Søren M., Vogelius, Ivan Richter, Specht, Lena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446040/
https://www.ncbi.nlm.nih.gov/pubmed/32216586
http://dx.doi.org/10.1080/0284186X.2020.1733654
_version_ 1783574098633293824
author Rechner, Laura Ann
Modiri, Arezoo
Stick, Line Bjerregaard
Maraldo, Maja V.
Aznar, Marianne C.
Rice, Stephanie R.
Sawant, Amit
Bentzen, Søren M.
Vogelius, Ivan Richter
Specht, Lena
author_facet Rechner, Laura Ann
Modiri, Arezoo
Stick, Line Bjerregaard
Maraldo, Maja V.
Aznar, Marianne C.
Rice, Stephanie R.
Sawant, Amit
Bentzen, Søren M.
Vogelius, Ivan Richter
Specht, Lena
author_sort Rechner, Laura Ann
collection PubMed
description Purpose: In current radiotherapy (RT) planning and delivery, population-based dose-volume constraints are used to limit the risk of toxicity from incidental irradiation of organs at risks (OARs). However, weighing tradeoffs between target coverage and doses to OARs (or prioritizing different OARs) in a quantitative way for each patient is challenging. We introduce a novel RT planning approach for patients with mediastinal Hodgkin lymphoma (HL) that aims to maximize overall outcome for each patient by optimizing on tumor control and mortality from late effects simultaneously. Material and Methods: We retrospectively analyzed 34 HL patients treated with conformal RT (3DCRT). We used published data to model recurrence and radiation-induced mortality from coronary heart disease and secondary lung and breast cancers. Patient-specific doses to the heart, lung, breast, and target were incorporated in the models as well as age, sex, and cardiac risk factors (CRFs). A preliminary plan of candidate beams was created for each patient in a commercial treatment planning system. From these candidate beams, outcome-optimized (O-OPT) plans for each patient were created with an in-house optimization code that minimized the individual risk of recurrence and mortality from late effects. O-OPT plans were compared to VMAT plans and clinical 3DCRT plans. Results: O-OPT plans generally had the lowest risk, followed by the clinical 3DCRT plans, then the VMAT plans with the highest risk with median (maximum) total risk values of 4.9 (11.1), 5.1 (17.7), and 7.6 (20.3)%, respectively (no CRFs). Compared to clinical 3DCRT plans, O-OPT planning reduced the total risk by at least 1% for 9/34 cases assuming no CRFs and 11/34 cases assuming presence of CRFs. Conclusions: We developed an individualized, outcome-optimized planning technique for HL. Some of the resulting plans were substantially different from clinical plans. The results varied depending on how risk models were defined or prioritized.
format Online
Article
Text
id pubmed-7446040
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74460402020-09-14 Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study Rechner, Laura Ann Modiri, Arezoo Stick, Line Bjerregaard Maraldo, Maja V. Aznar, Marianne C. Rice, Stephanie R. Sawant, Amit Bentzen, Søren M. Vogelius, Ivan Richter Specht, Lena Acta Oncol Original Articles: Radiotherapy and Radiobiology Purpose: In current radiotherapy (RT) planning and delivery, population-based dose-volume constraints are used to limit the risk of toxicity from incidental irradiation of organs at risks (OARs). However, weighing tradeoffs between target coverage and doses to OARs (or prioritizing different OARs) in a quantitative way for each patient is challenging. We introduce a novel RT planning approach for patients with mediastinal Hodgkin lymphoma (HL) that aims to maximize overall outcome for each patient by optimizing on tumor control and mortality from late effects simultaneously. Material and Methods: We retrospectively analyzed 34 HL patients treated with conformal RT (3DCRT). We used published data to model recurrence and radiation-induced mortality from coronary heart disease and secondary lung and breast cancers. Patient-specific doses to the heart, lung, breast, and target were incorporated in the models as well as age, sex, and cardiac risk factors (CRFs). A preliminary plan of candidate beams was created for each patient in a commercial treatment planning system. From these candidate beams, outcome-optimized (O-OPT) plans for each patient were created with an in-house optimization code that minimized the individual risk of recurrence and mortality from late effects. O-OPT plans were compared to VMAT plans and clinical 3DCRT plans. Results: O-OPT plans generally had the lowest risk, followed by the clinical 3DCRT plans, then the VMAT plans with the highest risk with median (maximum) total risk values of 4.9 (11.1), 5.1 (17.7), and 7.6 (20.3)%, respectively (no CRFs). Compared to clinical 3DCRT plans, O-OPT planning reduced the total risk by at least 1% for 9/34 cases assuming no CRFs and 11/34 cases assuming presence of CRFs. Conclusions: We developed an individualized, outcome-optimized planning technique for HL. Some of the resulting plans were substantially different from clinical plans. The results varied depending on how risk models were defined or prioritized. Taylor & Francis 2020-03-27 /pmc/articles/PMC7446040/ /pubmed/32216586 http://dx.doi.org/10.1080/0284186X.2020.1733654 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles: Radiotherapy and Radiobiology
Rechner, Laura Ann
Modiri, Arezoo
Stick, Line Bjerregaard
Maraldo, Maja V.
Aznar, Marianne C.
Rice, Stephanie R.
Sawant, Amit
Bentzen, Søren M.
Vogelius, Ivan Richter
Specht, Lena
Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
title Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
title_full Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
title_fullStr Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
title_full_unstemmed Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
title_short Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
title_sort biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
topic Original Articles: Radiotherapy and Radiobiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446040/
https://www.ncbi.nlm.nih.gov/pubmed/32216586
http://dx.doi.org/10.1080/0284186X.2020.1733654
work_keys_str_mv AT rechnerlauraann biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy
AT modiriarezoo biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy
AT sticklinebjerregaard biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy
AT maraldomajav biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy
AT aznarmariannec biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy
AT ricestephanier biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy
AT sawantamit biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy
AT bentzensørenm biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy
AT vogeliusivanrichter biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy
AT spechtlena biologicaloptimizationformediastinallymphomaradiotherapyapreliminarystudy